Drug intelligence / Profile preview

LY2590443

Development stage: Discontinued
Lead developer: Eli Lilly
Modality: Small Molecules
Administration: Oral

Overview

LY2590443 is a small molecule drug developed by Eli Lilly for the treatment of migraine disorders. It acts as an antagonist at the serotonin 7 (5-HT7) receptor and was also reported to antagonize the substance-P receptor (TACR1), both of which are implicated in migraine pathophysiology. The drug was administered orally and reached phase 2 clinical trials for acute migraine and headache disorders before development was discontinued. No brand or generic names beyond its code name have been reported.

Targets

TACR1 (Neurokinin‑1 Receptor)

Beyond the preview

Go deeper on LY2590443.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LY2590443.

Explore the full profile